Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE 68198, USA.
Cell Signal. 2013 Aug;25(8):1711-9. doi: 10.1016/j.cellsig.2013.03.025. Epub 2013 Apr 18.
Dissemination of cancer cells to distant organ sites is the leading cause of death due to treatment failure in different types of cancer. Mehlen and Puisieux have reviewed the importance of the development of inappropriate cell survival signaling for various steps in the metastatic process and have noted the particular importance of aberrant cell survival to successful colonization at the metastatic site. Therefore, the understanding of mechanisms that govern cell survival fate of these metastatic cells could lead to the understanding of a new paradigm for the control of metastatic potential and could provide the basis for developing novel strategies for the treatment of metastases. Numerous studies have documented the widespread role of Akt in cell survival and metastasis in colorectal cancer, as well as many other types of cancer. Akt acts as a key signaling node that bridges the link between oncogenic receptors to many essential pro-survival cellular functions, and is perhaps the most commonly activated signaling pathway in human cancer. In recent years, Akt2 and Akt3 have emerged as significant contributors to malignancy alongside the well-characterized Akt1 isoform, with distinct non-overlapping functions. This review is aimed at gaining a better understanding of the Akt-driven cell survival mechanisms that contribute to cancer progression and metastasis and the pharmacological inhibitors in clinical trials designed to counter the Akt-driven cell survival responses in cancer.
癌细胞扩散到远处的器官部位是导致不同类型癌症治疗失败后死亡的主要原因。Mehlen 和 Puisieux 回顾了不适当的细胞存活信号对转移过程中各种步骤的重要性,并指出异常细胞存活对转移部位成功定植的特别重要性。因此,了解控制这些转移性细胞的细胞存活命运的机制可能会导致对转移性潜力控制的新范式的理解,并为开发治疗转移的新策略提供基础。大量研究记录了 Akt 在结直肠癌以及许多其他类型癌症中的细胞存活和转移中的广泛作用。Akt 作为一个关键的信号节点,将致癌受体与许多重要的生存细胞功能联系起来,并且可能是人类癌症中最常被激活的信号通路。近年来,Akt2 和 Akt3 与特征明确的 Akt1 同工型一起,成为恶性肿瘤的重要贡献者,具有独特的非重叠功能。这篇综述旨在更好地理解 Akt 驱动的细胞存活机制,这些机制有助于癌症的进展和转移,以及临床试验中设计的药理学抑制剂,以对抗癌症中 Akt 驱动的细胞存活反应。